Jump to content

Turkovac: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎References: removed stub
mNo edit summary
Line 50: Line 50:


In June, TURKOVAC started on phase III trials with 40,800 participants in Turkey.<ref>{{#invoke:Cite web| |title=Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine |url=https://clinicaltrials.gov/ct2/show/NCT04942405 |website=[[ClinicalTrials.gov]] |date=28 June 2021 |id=NCT04942405 |access-date=29 June 2021 }}</ref>
In June, TURKOVAC started on phase III trials with 40,800 participants in Turkey.<ref>{{#invoke:Cite web| |title=Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine |url=https://clinicaltrials.gov/ct2/show/NCT04942405 |website=[[ClinicalTrials.gov]] |date=28 June 2021 |id=NCT04942405 |access-date=29 June 2021 }}</ref>

The [[Fahrettin Koca|Turkish Minister of Health]] said: that the vaccine has been approved for use in emergency cases <ref>{{Cite web|date=2021-11-25|title=Sağlık Bakanı Koca: TURKOVAC için acil kullanım onayına müracaat edildi|url=https://ortadoguhaberler.com/saglik-bakani-koca-turkovac-icin-acil-kullanim-onayina-muracaat-edildi/|access-date=2021-11-25|website=Orta Doğu Haberleri|language=tr}}</ref>


== References ==
== References ==

Revision as of 13:56, 25 November 2021

TURKOVAC
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesERUCOV-VAC
Routes of
administration		Intramuscular
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Society
virus icon COVID-19 portal

TURKOVAC[1] (pronunciation: [[Help:IPA/Turkish|['tɜ:rkəvæk]]]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.

Clinical trials

In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[3]

In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[4]

In June, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[5]

The Turkish Minister of Health said: that the vaccine has been approved for use in emergency cases [6]

References

  1. ^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
  2. ^ "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.
  3. ^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
  5. ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
  6. ^ "Sağlık Bakanı Koca: TURKOVAC için acil kullanım onayına müracaat edildi". Orta Doğu Haberleri (in Turkish). 25 November 2021. Retrieved 25 November 2021.
Scholia has a profile for TURKOVAC (Q106532118).
Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Turkovac&oldid=1057104939"